, 72 patients with non-Hodgkin's lymphoma or Hodgkin's disease underwent high-dose chemotherapy with autologous stem cell transplant conditioned with either cyclophosphamide, etoposide, carmustine (CEB) or carmustine, etoposide, cytarabine, melphalan (BEAM) at a single institution. In all, 52 patients received CEB and 20 patients received the BEAM regimen. Patient characteristics that were significantly different between the two groups are tumor grade and extranodal involvement (P ¼ 0.0196, 0.0341, respectively). Regimen-related toxicities examined yielded only diarrhea occurring at a higher rate in the BEAM group (81 vs 51%, P ¼ 0.0026), although cases were milder (92 vs 57%). Patients treated with CEB developed mucositis at a slightly higher rate (79%) than patients treated with BEAM (75%), but this difference did not reach statistical significance. However, the mucositis that occurred within the BEAM group was predominately mild (67%) in contrast to the predominance of moderate to severe cases in the CEB group (74%). In addition, patients treated with CEB required growth factor support for a longer time than patients treated with BEAM (P ¼ 0.0399). Response rates were high in both groups, with trends favoring the BEAM group. Overall survival was higher after treatment with BEAM than with CEB (84 vs 60%). A subset of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) have been treated with highdose chemotherapy with autologous stem cell transplant (HDC-ASCT). HDC regimens used include cyclophosphamide, etoposide, carmustine (BCNU) (CEB) or BCNU, etoposide, cytarabine (Ara-C), and melphalan (BEAM). In the past, CEB has been more commonly used at our institution; however, in recent years, oncologists are increasingly choosing BEAM to treat patients. The increased use of BEAM emerges from the belief that reduced toxicities are associated with this regimen, namely less mucositis, infection, and BCNU pulmonary fibrosis. A higher dose of BCNU (600 mg/m 2 ) is given as part of the CEB regimen than that given in the BEAM regimen (300 mg/m 2 ). Doses greater than 600 mg/m 2 are not well tolerated with a higher risk of development of posttransplant noninfective pulmonary complications, marked mucositis, and increased cases of infection. [1] [2] [3] [4] [5] [6] In terms of efficacy, whether CEB or BEAM produces better survival outcome is unclear. There is a wide range of percentages of patients achieving complete remission in both the CEB and BEAM. 2, 3, [7] [8] [9] Overall survival at 5 years seems comparable at 44-53% for CEB patients and 41-55% for BEAM patients. 3, [8] [9] [10] [11] Progression-free survival ranges from 38 to 450% for the CEB group and from 35 to 69% for the BEAM group in various studies. [2] [3] [4] [7] [8] [9] 11 Data directly comparing CEB and BEAM regimens are scarce. In this paper, we present the results of a retrospective study on the toxicity, efficacy, and cost issues associated with the use of CEB and BEAM in patients with NHL or HD.
A subset of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) have been treated with highdose chemotherapy with autologous stem cell transplant (HDC-ASCT). HDC regimens used include cyclophosphamide, etoposide, carmustine (BCNU) (CEB) or BCNU, etoposide, cytarabine (Ara-C), and melphalan (BEAM). In the past, CEB has been more commonly used at our institution; however, in recent years, oncologists are increasingly choosing BEAM to treat patients. The increased use of BEAM emerges from the belief that reduced toxicities are associated with this regimen, namely less mucositis, infection, and BCNU pulmonary fibrosis. A higher dose of BCNU (600 mg/m 2 ) is given as part of the CEB regimen than that given in the BEAM regimen (300 mg/m 2 ). Doses greater than 600 mg/m 2 are not well tolerated with a higher risk of development of posttransplant noninfective pulmonary complications, marked mucositis, and increased cases of infection. [1] [2] [3] [4] [5] [6] In terms of efficacy, whether CEB or BEAM produces better survival outcome is unclear. There is a wide range of percentages of patients achieving complete remission in both the CEB and BEAM. 2, 3, [7] [8] [9] Overall survival at 5 years seems comparable at 44-53% for CEB patients and 41-55% for BEAM patients. 3, [8] [9] [10] [11] Progression-free survival ranges from 38 to 450% for the CEB group and from 35 to 69% for the BEAM group in various studies. [2] [3] [4] [7] [8] [9] 11 Data directly comparing CEB and BEAM regimens are scarce. In this paper, we present the results of a retrospective study on the toxicity, efficacy, and cost issues associated with the use of CEB and BEAM in patients with NHL or HD.
Patients and methods

Patient selection
A total of 86 patients with NHL or HD underwent highdose CEB or BEAM chemotherapy followed by ASCT at the University of California, San Diego (UCSD) Thornton Hospital between January 1996 and July 2002, as identified from the bone marrow transplant database at UCSD. A total of 72 patients were included in the study, which was approved by the institutional review board of UCSD. In all, 52 patients received CEB and 20 patients received BEAM as their high-dose conditioning regimen. The inclusion criteria were diagnosis of NHL according to the REAL classification or diagnosis of HD, patients naı¨ve to ASCT, and availability of patients' medical records.
Patient characteristics
Patient characteristics are listed in Table 1 . The listed concomitant medical conditions were reported in the patient's medical history. Hepatic impairment included elevated liver enzymes, hepatitis, cirrhosis, and pre-existing veno-occlusive disease (VOD). Renal impairment included elevations in serum creatinine above 1.5 mg/dl. Two patients' diagnoses of lymphoma subtype were not found.
The percentages of patients with NHL presenting with B symptoms at diagnosis were 55% in the CEB group and 56% in the BEAM group. Percentage of patients in the CEB group with a performance status of 0-1 was 95% and CD34 þ cells/kg, respectively). Supportive care included MESNA in the CEB group for uroepithelial prophylaxis, mouth care, and antiemetics. Broad-spectrum antibiotics consisted of ciprofloxacin 500 mg every 12 h and acyclovir 400 mg every 12 h (HSV positive) starting on day þ 1. For febrile neutropenic patients, ceftazidime 1 g every 8 h was started, as well as vancomycin, if line site infection was suspected. A total of 60 patients (83%) received granulocyte colony-stimulating factor (G-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) post transplantation. The dose was started on day þ 5 and continued until ANC 4500. There were also protocols in place for platelet transfusion, electrolyte replacement, and diarrhea.
Regimen-related toxicity
Regimen-related toxicities (RRTs) were recorded to evaluate the toxicity of CEB and BEAM as high-dose conditioning regimens. Diarrhea was categorized according to mild (grades 0-1), moderate (grade 2), and severe (grades 3-4). Objective grading of diarrhea was difficult to find in all cases; in such situations, the severity was ranked based on descriptions of the diarrhea, quality, duration, need for, and type of antidiarrheal agents needed. Pulmonary toxicity was defined from documented written record in the patient's chart, attributing the direct cause to BCNU. Supporting evidence included records of positive chest radiograph, clinical signs and symptoms, and steroid treatment. Infections were documented from microbiology reports and progress notes. The length of time to resolve neutropenia was counted from the day the patient became neutropenic to the day their neutropenia resolved (absolute neutrophil count (ANC) 40.5 Â 10 9 /l). Due to inconsistency in the definition of resolved thrombocytopenia, data on length of thrombocytopenia were omitted.
Study definitions
Overall survival (OS) was calculated from the time of transplantation to the time of death or last follow-up. Progression-free survival (PFS) was calculated from the time of transplantation to the time of disease progression, last follow-up, or death. Disease-free survival (DFS) was calculated from the time of transplantation to the time of disease progression, last follow-up, or death in patients who attained complete remission.
Statistical analysis
All data collected for this study were analyzed using the Statistical Analysis System (SAS) program. Statistical significance for all tests was defined as P-value o0.05. Percentages for all calculations were based on the total number of patients for whom that specific information is found in medical records; as such, total numbers may not add up every time to the number of patients in the CEB (n ¼ 52) and BEAM (n ¼ 20) groups, respectively. Continuous variables identified were age, number of years since diagnosis, number of chemotherapeutic regimens prior to HDC-ASCT, number of CD34 þ cells injected, length of follow-up, time to death, length of hospital stay, length of growth factor use, and length of total parenteral nutrition (TPN) use. Continuous variables were analyzed using the nonparametric Wilcoxon two-sample test to test whether the distribution of the variable has the same location parameter across the CEB and BEAM groups. The SAS procedure NPAR1WAY was used to perform analysis of variance on ranks of the continuous variables, and a twosided t approximation was used for testing. Due to small sample size, w 2 test may not be valid. Therefore, two-tailed Fisher's exact tests were performed for all remaining variables. The 2 Â 2 contingency tables compared patient characteristics, RRT, efficacy, and cost between the CEB and BEAM regimens. Many variables have been further subcategorized for analysis. For example, in comparing outcomes between CEB and BEAM, subcategories of the outcome variable are complete remission (CR), partial remission (PR), disease progression (DP), and stable disease (SD). Due to the nature of the test, when statistical significance is detected, it can only be concluded that this variable is significantly different between CEB and BEAM; statistical significance cannot be carried over into the subcategory level. Analysis of survival data was performed using Cox regressions. The PHREG procedure in SAS identified the important prognostic factors from a large number of candidate variables. Time to death and time to disease progression were the dependent variables in two separate analyses. The explanatory variables examined in this multivariate analysis were age, gender, race, type of lymphoma, HDC regimen, extranodal involvement, number of chemotherapy regimens prior to HDC-ASCT, history of prior CR, status prior to HDC-ASCT, mucositis, pulmonary toxicity, liver toxicity, and number of bacterial/ viral/fungal infections. Pearson correlation coefficients were calculated between all independent variables and the dependent variables.
Results
The median time of follow-up of a patient's disease course post transplant was 10 months (range 1-81 months) for the CEB group and 10.5 months (range 2-62 months) for the BEAM group. The mean follow-up time was 15.6 and 16.7 months, respectively.
Toxicity
RRT are listed in Table 2 . Six cases of diarrhea were attributed to Clostridium difficile in the CEB group vs one case of C. difficile in the BEAM group. Coagulase-negative Staphylococcus was the most common infecting organism. There were two cases of Pseudomonal infections in CEB patients. Other infecting organisms included Escherichia coli and Streptococcus species. There were three cases of bacteremia in the BEAM group and eight cases in the CEB group. Hepatotoxicity (elevations in liver enzymes, bilirubin) occurred in nine patients in the CEB group, two of whom later developed fatal VOD. Renal toxicity included new cases of renal impairment post transplant. Cardiovascular complications were arrhythmias and heart failure. CNS toxicities were absent in both groups. Ophthalmologic adverse effects included visual changes.
Response, survival, and prognostic factors
Response to HDC-ASCT and survival characteristics are summarized in Table 3 . On multivariate analysis, patients who received CEB were 11 times more likely to have faster DP. Number of viral infections, occurring only in the CEB group, liver toxicity, and age 450 years were also significant predictors of faster DP. CEB is a strong predictor of poor survival. CEB patients were 49 times more likely to die sooner than BEAM patients. Other Table 2 Regimen-related toxicity 
Cost issues
Length of hospital stay averaged 21 days in the CEB group and 22 days in the BEAM group. There was a significant difference in the duration of GCSF/GMCSF use between the two groups (P ¼ 0.0399). Patients who received CEB required an average of 8 days of use vs patients who received BEAM who required an average of 4 days. Seven patients required TPN initiation following transplantation; all had received the CEB regimen.
Discussion
Two RRT, mucositis and diarrhea occurred in a similar distribution between the CEB and BEAM groups. Difference in the incidence of diarrhea between the two patient groups reached a level of significance. More cases of diarrhea occurred in the BEAM group (81%) vs that in the CEB group (51%); however, out of those patients who experienced diarrhea, BEAM patients had milder cases (92%) than CEB patients (57%). Although mucositis occurred only slightly more frequently with the CEB regimen (79%) than with the BEAM regimen (75%), the mucositis that occurred within the BEAM group was predominantly mild (67%) in contrast to the predominance of moderate to severe cases in the CEB group (74%). All cases of patients requiring TPN were in the CEB group. Mucositis is a major toxicity of etoposide and BCNU; previous authors have described marked mucositis requiring narcotics and parenterals occurring with the CEB regimen, which usually contains at least double the doses of etoposide and BCNU than does the BEAM regimen.
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Indeed, Wheeler et al, in a CEB dose-finding study, found that the number of severe cases of mucositis doubled (10-20%) when the BCNU dose was increased from 450 to 600 mg/m 2 . It is interesting to note that when etoposide is infused as a continuous infusion rather than as boluses in the CEB regimen, the dose can be pushed to 2400 mg/m 2 while reducing the mucositis occurrence rate to 1%. 8 In previous studies, the BEAM regimen with conventional doses of BCNU and etoposide (300 and 800 mg/m 2 , respectively) produced rates of mucositis ranging from 25% to universal occurrence. 7, 9 One study reported severe mucositis to occur at 7%, which is consistent with our low rate of severe mucositis in the BEAM group (13%).
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Although the length of growth factor use was significantly different between the CEB and BEAM groups, Pearson's correlation coefficients did not show significant association Table 3 Response to treatment with the incidence of mucositis. In a comparison between BEAM and BEAC, a regimen in which melphalan is substituted by cyclophosphamide, Jantunen et al observed more cases of mucositis, diarrhea, and septicemia with BEAM, and emphasized the importance of reducing mucosal toxicity during the neutropenic period to decrease the frequency of bacteremia with its associated risk of complications. In our study, although a higher incidence of diarrhea occurred with BEAM than CEB with a similar incidence of mucositis, the frequency of bacteremia was similar at approximately 16%. Overall, although not statistically significant, patients who received CEB developed more infections than patients who received BEAM. Bacterial infections occurred more often in the CEB group (46 vs 39%) than in the BEAM group, there were more fungal infections at 8 vs 6%, and all viral infections occurred in the CEB group at an incidence of 10%. Again, Wheeler et al attributed this increased occurrence to dose escalation of BCNU. When 450 mg/m 2 BCNU was given, the incidence of infection was 5%; when the dose was increased to 600 mg/m 2 , the rate rose to 12%. Patients in the CEB group did display a trend of slower engraftment following HDCASCT. However, Pearson correlation coefficients calculated between the length of growth factor use and number of infections did not show any significance. Of interest is the low occurrence rate of BCNU pulmonary toxicity from CEB. Both regimens led to development of this complication at low rates (8% after CEB and 11% after BEAM). It is unlikely that patients who would have developed this toxicity were missed due to insufficient follow-up time. It is also unlikely that this result occurred due to small sample size. Previous studies have included small numbers of patients but reported roughly 26-28% occurrence of post-transplant noninfective pulmonary complications with CEB. 1, [5] [6] These studies used a BCNU dose of 600 mg/m 2 or higher. It is apparent from these studies that BCNU pulmonary toxicity is dose related, but it remains unclear why our study reports a low occurrence rate. Some authors comment that this complication occurs more commonly with a total dose of BCNU 41400 mg/m 2 . 12 Risk factors favoring BCNU lung toxicity have been reported, including previous treatment with bleomycin or chest radiotherapy and the female gender. 1 Half (3/6) of our patients who developed BCNU pulmonary toxicity had previously received bleomycin, although it is unknown whether they had experienced any pulmonary complications at that time. The number of other patients who had received bleomycin as earlier treatment and had been spared toxicity with BCNU given presently is unknown. Liver toxicity occurred at a higher rate in the CEB group than in the BEAM group (18 vs 6%). Authors have commented that lower dosing of BCNU decreases hepatotoxicity while preserving outcome. 8 In addition, high-dose etoposide commonly causes hepatocellular damage. 12 Factors influencing neutropenia include age, degree of compromise from previous chemotherapy or radiation, nutritional status, and liver/kidney function. 14 Since there was no detectable difference in these patient characteristics between the CEB and BEAM groups, we did not observe a difference in the length of neutropenia between the two HDC regimens. Treatment-related mortality in our study was low (6% in the CEB group and 11% in the BEAM group) compared to previous studies (19-21% in the CEB group and 7-10% in the BEAM group). 3, 8, 9, 11, 13 Of note, higher doses of cyclophosphamide and etoposide as part of the CEB regimen were used in those studies in comparison to our study. In addition, this observation may be due to the limitation of a retrospective study to identify mortality as a direct result of the treatment as patients were lost to follow-up after a mean of 16 months. Survival data seem to favor the BEAM regimen. Patients who received BEAM or CEB appeared equally likely to achieve overall response (CR þ PR ¼ 82% vs BEAM CR þ PR ¼ 80%), but all BEAM patients who responded achieved CR in contrast to only 63% of CEB patients. Reports of CR to the CEB regimen in the literature range widely from 33 to 80%, depending on the doses of cyclophosphamide and etoposide used. 2, 3, 6, 8, 15 Reports of CR to the BEAM regimen also range widely from 28 to 92%. 7, 9, 11, 16 Various authors have commented on prognostic factors for treatment success. Salar et al 17 previously described the importance of disease status at the time of transplant. In addition, they found that response to first-line therapy, number of first-line regimens, number of extranodal sites, and tumor stage correlate with DFS. Predicted OS at 8 years (median follow-up 28 months) favored the BEAM regimen over the CEB (CBV) regimen (58 vs 40%). Arranz et al, 18 on univariate analysis, found that absence of extranodal disease and CR status at transplant were associated with better PFS. In our study, more patients in the CEB group were in CR at the time of ASCT than in the BEAM group, and more CEB patients had a history of prior CR than BEAM; however, more patients who received CEB had extranodal disease than patients who received BEAM (55 vs 20%, Po0.05). The actual OS (mean follow-up16 months) of BEAM patients was greater than CEB patients (84 vs 60%), and DP occurred faster in CEB patients than in BEAM patients (38% of CEB patients had DP within 1-6 months vs 6% of BEAM patients). It is difficult to assess which regimen produced better survival. The small number of BEAM patients and the distribution of low-grade NHL and early-stage HD skewing towards the BEAM group must also be considered. In this study, the CEB regimen carries more toxicity than does the BEAM regimen. Also, its use is associated with higher cost. Comparison of efficacy between CEB and BEAM is less clear. Interpretation of results is difficult since there are confounding factors. Due to limitations of a retrospective study, data on all variables were often hard to obtain and many factors could not be controlled. The small number of patients who received the BEAM regimen relative to the CEB regimen should be considered when interpreting results. In addition, caution should be exercised when applying these data to patients with HD, since only 12 patients fit into this category. 19 While this study documents the initial evidence of toxicities and outcomes associated with the two regimens, a prospective study with adequate numbers of patients may be able to equalize the proportion of patients in the CEB and BEAM groups and provide systematic evaluation of patients on either regimen. 20 
